Diagnosis & Disease Information

The median cancer-specific survival was 56.5 months.

The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab.

Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.

Patients with smaller target lesions at baseline were more likely to be long-term survivors.

Iodine concentration and Hounsfield units were associated with treatment response and survival.

It was previously unknown whether the survival benefits seen with lenvatinib plus pembrolizumab persisted in the long term.